FDA RECALLS & COURT ACTIONS: November 17, 1993
Executive Summary
CLASS II -- DMSA KIDNEY REAGENT KIT For the preparation of Technetium TC99m Succimer Injection, Rx intravenous sterile diagnostic radiopharmaceutical. Recall number: D-023-4. Lot numbers: 002, 002A, 002B. Manufacturer Amersham International plc, Gloucester, England. Recalled by: Medi-Physics, Inc., Arlington Heights, Illinois, by letter Oct. 12, 1993. Firm- initiated recall ongoing. Distribution: Nationwide, Canada; 724 kits were distributed; firm estimates 150 kits remain on the market. Reason: Kits bear an expiration date of March 24, 1994 instead of Sept. 24, 1993. CLASS II -- VIDEX (DIDANOSINE) CHEWABLE/DISPERSIBLE BUFFERED TABLETS, 25 MG In 60 tablet bottles, Rx, used in the treatment of AIDS. Recall number D-025-4. Batch code MBE15. Manufacturer: Bristol-Myers Squibb Company, Evansville, Indiana. Recalled by: Bristol-Myers Squibb HIV Products, Princeton, New Jersey, by letter June 3, 1993. Firm- initiated recall complete. Distribution: Nationwide; 207 cases (12 bottles per case) were distributed. Reason: Product does not meet content uniformity specifications. CLASS III -- NOVAFED Brown and orange colored hard gelatin capsules, in bottles of 100, a controlled-release Rx decongestant. Recall number: D-024-4. Lot number 1127BC EXP 12/94. Manufacturer: KV Pharmaceuticals, St Louis, Missouri. Recalled by: Marion Merrell Dow, Inc., Cincinnati, Ohio, by letter Oct. 7, 1993. Firm-initiated recall ongoing. Distribution: Nationwide and Puerto Rico; 19,467 bottles were distributed; firm estimates very little stock remains on the market. Reason: Product failed stability testing for dissolution.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth